CAG
XLRN

Crestwood Advisors Group’s Acceleron Pharma XLRN Stock Holding History

Crestwood Advisors Group’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-194
Closed -$6K – 466
2017
Q1 		$6K Buy
+194
New +$5.11K ﹤0.01% 473

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Crestwood Advisors Group's XLRN Position: Q2 2017 in Review

Crestwood Advisors Group sold out of Acceleron Pharma (XLRN) in Q2 2017, closing a stake of 194 shares — an estimated $6K sold.

Crestwood Advisors Group first reported a position in XLRN in Q1 2017 and held it in 1 quarter. The position peaked at $6K in Q1 2017. 128 funds tracked by Wall St. Rank hold XLRN as of Q2 2017.

  • Crestwood Advisors Group reported no remaining Acceleron Pharma position as of Q2 2017 after selling out during the quarter.
  • Crestwood Advisors Group sold 194 Acceleron Pharma shares in Q2 2017, an estimated $6K.
  • Crestwood Advisors Group first reported a position in Acceleron Pharma in Q1 2017 and held it in 1 quarter.
  • Crestwood Advisors Group's Acceleron Pharma position peaked at $6K in Q1 2017.
  • 128 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2017.

Based on Crestwood Advisors Group's 13F filing for Q2 2017, filed 31 Jul 2017.